Por: Fox Business Business January 07, 2023
Check out what's clicking on FoxBusiness.com An Alzheimer’s drug from has received accelerated approval from the Food and Drug Administration (FDA), the companies and agency announced Friday. Lecanemab appeared to reduce brain amyloid plaque — a marker of Alzheimer’s — in a 865-patient study involving people with mild cognitive impairment or mild dementia stage of the disease and confirmed presence of amyloid beta pathology that... + full article
CNBC USA Health January 06, 2023
In this articleMRI image of brain showing area of Alzheimer patient.Getty ImagesThe Food and Drug Administration on Friday granted accelerated approval for the Alzheimer's drug lecanemab, the second treatment from and its Japanese partner Eisai to receive an early green... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
FDA Approves Alzheimer's Drug That Slowed Cognitive Decline in Clinical Trial | NBC 6 South Florida
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
ABC News USA Business September 29, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after ’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
How To Spot The Early Signs Of Alzheimer's | Newsweek
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
WPLG Local 10 USA Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab,... + más
Associated Press USA Health September 28, 2022
About iurex | Privacy Policy | Disclaimer |